The purpose of our study was to evaluate the feasibility of salvage surgery for patients with persistent or recurrent maxillary sinus cancer after superselective intra-arterial cisplatin infusion with concomitant radiotherapy (RADPLAT). We retrospectively analyzed 61 patients with maxillary sinus cancer who underwent RADPLAT.
Introduction
Maxillary sinus cancer is not common, comprising only about 3% of all head and neck cancer and about 0.5% of all malignant disease. The annual incidence rate is 0.5-1.0 per 100,000 population, and squamous cell carcinoma is the most frequent histologic type and was found in 57% of patients with maxillary sinus cancer [1] [2] [3] .
Many authors have recommended combined therapies consisting of en bloc radical resection together with irradiation [4] [5] [6] . However, the cosmetic problems for patients undergoing en bloc resection are significant. Therefore, multi-modality treatments have been introduced to avoid cosmetic problems as well as to preserve ocular function and to improve patient outcomes. In Japan, superselective intra-arterial cisplatin infusion with concomitant radiotherapy (RADPLAT) has been introduced to preserve the orbital contents and ocular function in patients with advanced maxillary sinus cancer [7, 8] . This non-surgical treatment has been reported to be both safe and highly effective.
Salvage surgery is generally attempted, when localized persistent or recurrent primary tumors are observed after initial chemoradiotherapy [9] [10] [11] [12] . However, there have been no reports of salvage surgery for patients with persistent/recurrent maxillary sinus cancer after intensive chemoradiotherapy to date. The purpose of our study was to evaluate the feasibility of salvage surgery as well as prove its efficacy for patients with persistent/recurrent maxillary sinus cancer after RADPLAT.
Method
Patients. We retrospectively analyzed 61 patients with maxillary sinus squamous cell carcinomas who underwent RADPLAT in Hokkaido University Hospital, Japan between September 1999 and July 2012. T and N stages were classified according to the American Joint Committee on Cancer (AJCC) staging system 2010. Table 1 
Results
Chemoradiotherapy. Intra-arterial chemotherapy was performed a median 4 times. The median irradiation dose was 65 Gy. Fifty-eight patients (95%) underwent a full course of irradiation (>65 Gy). In one patient, RADPLAT was cancelled due to severe neutropenia and sepsis after the second intra-arterial cisplatin infusion, and palliative treatment was administered. In another patient, ischemic colitis developed after the first intra-arterial chemotherapy. Intra-arterial chemotherapy was, therefore, suspended, and he underwent 50 Gy of radiotherapy followed by salvage surgery. In the final patient, intra-arterial chemotherapy was performed four times. However, he chose to suspend the subsequent radiation therapy after receiving 48 Gy of irradiation out of concern for severe late complications of radiotherapy. Of the 17 patients with persistent/recurrent primary disease, salvage surgery was not performed in 6 patients (35.3%). Details of these patients are shown in Table 2 .
Various chemotherapies were used for three patients according to their general conditions. Only one patient, who received adjunctive chemotherapy, remains alive with primary disease.
The 5-year overall survival rate of all 61 patients was 68.1%. The 5-year local control rate by RADPLAT and salvage surgery was 81.3% ( Figure 2) . Figure 3 shows the overall survival curves for the 17 patients with persistent/recurrent primary disease, the 11 patients undergoing salvage surgery, and the 6 patients not receiving salvage surgery. The 5-year overall survival rate of the 11 patients undergoing salvage surgery was calculated to be 60.6% by the Kaplan-Meier method.
Salvage surgery. Salvage surgery was performed for 11 patients at a median 4.2 months (range, 1 to 46 months) after the completion of RADPLAT. Details of the salvage surgery are given in Table 3 . Seven of the 11 patients underwent total maxillectomy with a Weber-Ferguson skin incision. Skull base resection and endoscopic partial maxillectomy was performed in one patient, and the remaining three patients underwent partial maxillectomy. Post-operative complications (Grade 2-4) were observed in two patients (18.2%), comprising deep vein thrombosis (Grade 2) in one patient and local infection and sepsis (Grade 3) in the other.
Discussion
For most maxillary sinus squamous cell carcinomas, a combination of radical surgery and preoperative or postoperative radiation therapy constitute the standard treatment. Total maxillectomy, with or without orbital exenteration, is the most commonly performed surgical operation for maxillary sinus cancers. However, functional and cosmetic outcomes after surgical treatment for patients with advanced tumors are also far from satisfactory from the patient standpoint. In our institution, RADPLAT was attempted to preserve ocular function and avoid cosmetic problems for patients with advanced maxillary sinus cancer who hoped to undergo non-surgical treatment. In particular, we think that the unresectable tumors or the tumors with orbital invasion may be a good indication for RADPLAT. In Japan, RADPLAT has been reported to be both safe and effective for patients with maxillary sinus cancer [7, 8] .
However, additional treatment is often problematic when persistent/recurrent maxillary sinus cancer is observed. We, therefore, focused on salvage surgery for patients with persistent/recurrent maxillary sinus cancer after RADPLAT, and evaluated the feasibility of salvage surgery after RADPLAT in terms of the complication rate and salvage rate.
The complication rate of salvage surgery after intensive chemoradiation therapy for patients with head and neck cancer was reported to be 11%-63.2% [7] [8] [9] [10] .
In 1998, Curran et al. reported salvage surgery after radiotherapy for patients with paranasal malignancies [13] . In this article, the complication rate of salvage surgery was indicated to be 24%. In our current study, the post-operative complication rate was 18.2%, which is comparable to those published in recent reports. Therefore, salvage surgery after RADPLAT is considered to be both safe and feasible.
Intensive chemoradiation therapy, such as RADPLAT is available for the purpose of avoiding surgical stress. However, salvage surgery may be almost the only alternative for the treatment against persistent/recurrent primary disease after intensive chemoradiation therapy. It was reported that salvage surgery for persistent/recurrent cancer of head and neck can be difficult in terms of surgical technique, and has not only high complication rates but also low salvage rates [14, 15] . In addition, salvage surgery for patients with recurrent upper-aerodigestive-tract cancer may frequently lead to fistula formation and/or severe infectious complications, which may cause carotid artery bleeding or prolong hospitalization. In cases of persistent/recurrent maxillary sinus cancer, we believe that salvage surgery is safer as there is no potential for fistula formation associated with maxillectomy. Persistent/recurrent primary disease was controlled in 8 of 11 patients undergoing salvage surgery (72.7%). Seven of the 17 patients with persistent/recurrent maxillary sinus cancer (41.2%) have survived without any evidence of disease after undergoing salvage surgery. The cause of this favorable salvage rate might be that persistent/recurrent primary disease is frequently localized and oncologically resectable after RADPLAT in patients with maxillary sinus cancer.
In conclusion, salvage surgery for patients with persistent/recurrent maxillary cancer after RADPLAT is considered to be safe and successful. We further considered that the overall survival rate of patients undergoing salvage surgery is favorable (60.6%), and that salvage surgery is a good option in cases where persistent/recurrent maxillary sinus cancer is observed after RADPLAT. It is also important to recognize persistent/recurrent primary disease as soon as possible so as not to miss the opportunity to perform salvage surgery.
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